Literature DB >> 26280944

Effect of Presymptomatic Body Mass Index and Consumption of Fat and Alcohol on Amyotrophic Lateral Sclerosis.

Mark H B Huisman1, Meinie Seelen1, Perry T C van Doormaal1, Sonja W de Jong1, Jeanne H M de Vries2, Anneke J van der Kooi3, Marianne de Visser3, H Jurgen Schelhaas4, Leonard H van den Berg1, Jan H Veldink1.   

Abstract

IMPORTANCE: Because dietary intake may influence pathophysiologic mechanisms in sporadic amyotrophic lateral sclerosis (ALS), the association between premorbid dietary intake and the risk of sporadic ALS will provide insight into which mechanisms are possibly involved in ALS pathophogenesis.
OBJECTIVE: To systematically determine the association between premorbid dietary intake and the risk of sporadic ALS. DESIGN, SETTING, AND PARTICIPANTS: A population-based case-control study was conducted in a general community setting in the Netherlands from January 1, 2006, to September 30, 2011. Analysis was conducted April 1, 2013, to November 15, 2014. All patients with a new diagnosis of possible, probable (laboratory supported), or definite ALS according to the revised El Escorial criteria were included and multiple sources were used to ensure complete case ascertainment. Of 986 eligible patients, 674 gave informed consent and returned a complete questionnaire; 2093 controls randomly selected from the general practitioners' registers and frequency matched to the patients for sex and age were included. MAIN OUTCOMES AND MEASURES: We studied the premorbid intake of nutrients in association with the risk of ALS by using a 199-item food frequency questionnaire adjusted for confounding factors and corrected for multiple comparisons while minimizing recall bias.
RESULTS: Presymptomatic total daily energy intake in patients, reported as mean (SD), was significantly higher compared with controls (2258 [730] vs 2119 [619] kcal/day; P < .01), and presymptomatic body mass index (calculated as weight in kilograms divided by height in meters squared) was significantly lower in patients (25.7 [4.0] vs 26.0 [3.7]; P = .02). With values reported as odds ratio (95% CI), higher premorbid intake of total fat (1.14; 1.07-1.23; P < .001), saturated fat (1.43; 1.25-1.64; P < .001), trans-fatty acids (1.03; 1.01-1.05; P < .001), and cholesterol (1.08; 1.05-1.12; P < .001) was associated with an increased risk of ALS; higher intake of alcohol (0.91; 0.84-0.99; P = .03) was associated with a decreased risk of ALS. These associations were independent of total energy intake, age, sex, body mass index, educational level, smoking, and lifetime physical activity. No significant associations between dietary intake and survival were found. CONCLUSIONS AND RELEVANCE: The combination of independent positive associations of a low premorbid body mass index and a high fat intake together with prior evidence from ALS mouse models transgenic for SOD1 and earlier reports on premorbid body mass index support a role for increased resting energy expenditure before clinical onset of ALS.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26280944     DOI: 10.1001/jamaneurol.2015.1584

Source DB:  PubMed          Journal:  JAMA Neurol        ISSN: 2168-6149            Impact factor:   18.302


  36 in total

Review 1.  Defining pre-symptomatic amyotrophic lateral sclerosis.

Authors:  Michael Benatar; Martin R Turner; Joanne Wuu
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2019-03-20       Impact factor: 4.092

2.  Participation in Physical Activity and Risk for Amyotrophic Lateral Sclerosis Mortality Among Postmenopausal Women.

Authors:  Yvonne L Eaglehouse; Evelyn O Talbott; Yuefang Chang; Lewis H Kuller
Journal:  JAMA Neurol       Date:  2016-03       Impact factor: 18.302

Review 3.  Physiological changes in neurodegeneration - mechanistic insights and clinical utility.

Authors:  Rebekah M Ahmed; Yazi D Ke; Steve Vucic; Lars M Ittner; William Seeley; John R Hodges; Olivier Piguet; Glenda Halliday; Matthew C Kiernan
Journal:  Nat Rev Neurol       Date:  2018-03-23       Impact factor: 42.937

Review 4.  Altered Bioenergetics and Metabolic Homeostasis in Amyotrophic Lateral Sclerosis.

Authors:  Andrew T Nelson; Davide Trotti
Journal:  Neurotherapeutics       Date:  2022-06-30       Impact factor: 6.088

5.  Gene expression profiles in sporadic ALS fibroblasts define disease subtypes and the metabolic effects of the investigational drug EH301.

Authors:  Jasmine A Fels; Gabriella Casalena; Csaba Konrad; Holly E Holmes; Ryan W Dellinger; Giovanni Manfredi
Journal:  Hum Mol Genet       Date:  2022-10-10       Impact factor: 5.121

6.  Cognition and eating behavior in amyotrophic lateral sclerosis: effect on survival.

Authors:  R M Ahmed; J Caga; E Devenney; S Hsieh; L Bartley; E Highton-Williamson; E Ramsey; M Zoing; G M Halliday; O Piguet; J R Hodges; M C Kiernan
Journal:  J Neurol       Date:  2016-06-03       Impact factor: 4.849

Review 7.  Body mass index and survival from amyotrophic lateral sclerosis: A meta-analysis.

Authors:  Efthimios Dardiotis; Vasileios Siokas; Maria Sokratous; Zisis Tsouris; Athina-Maria Aloizou; Desponia Florou; Metaxia Dastamani; Alexios-Fotios A Mentis; Alexandros G Brotis
Journal:  Neurol Clin Pract       Date:  2018-10

8.  Neural correlates of fat preference in frontotemporal dementia: translating insights from the obesity literature.

Authors:  Rebekah M Ahmed; Nga Yan Tse; Yu Chen; Elana Henning; John R Hodges; Matthew C Kiernan; Muireann Irish; I Sadaf Farooqi; Olivier Piguet
Journal:  Ann Clin Transl Neurol       Date:  2021-05-11       Impact factor: 4.511

9.  Altered expression of clock and clock-controlled genes in a hSOD1-linked amyotrophic lateral sclerosis mouse model.

Authors:  Kelby M Killoy; Mariana Pehar; Benjamin A Harlan; Marcelo R Vargas
Journal:  FASEB J       Date:  2021-02       Impact factor: 5.834

10.  NR1D1 downregulation in astrocytes induces a phenotype that is detrimental to cocultured motor neurons.

Authors:  Kelby M Killoy; Benjamin A Harlan; Mariana Pehar; Marcelo R Vargas
Journal:  FASEB J       Date:  2022-04       Impact factor: 5.834

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.